Announcement • May 16
Ludwig Enterprises, Inc. announced delayed 10-Q filing On 05/15/2026, Ludwig Enterprises, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Oct 02
Ludwig Enterprises, Inc. Appoints Jose Antonio Reyes as Interim Chief Executive Officer, Effective October 1, 2025 On October 1, 2025, the Board of Directors of Ludwig Enterprises, Inc. appointed Jose Antonio Reyes to serve as the Company’s Interim Chief Executive Officer. Mr. Reyes currently serves as the Senior Head of Global Business Development and will continue in that role as well. Mr. Reyes served as Chief Executive Officer between August 2024 and April 2025. Prior to becoming CEO, Mr. Reyes served as COO from February 2023 until taking over as CEO. From 2017 through 2023, Mr. Reyes served as Director of Executive Relations & Business Development for BlockScience, Inc., where his duties included overseeing the development of internal communications, hiring, monitoring and quality control systems. Mr. Reyes has over 30 years of leadership experience across national and international markets. Previously, Mr. Reyes co-founded and led IGM Global Inc., an executive education media company that provides insights into disruptive technologies and their industry impacts. He also founded Excelorators, Inc., offering corporate leadership development programs at prestigious institutions such as Harvard, MIT, Stanford, and West Point. Additionally, he was the Chief Strategy Officer for Trademark Tours, which specializes in private hospitality and customized education services at Harvard University. Reyes holds an MA in Communication and Media Studies and an MA in Biblical Studies from Regent University, along with a BA in Public Policy-Telecommunications from Duke University. Announcement • Jun 26
Ludwig Enterprises, Inc. Appoints Garth Lees-Rolfe as New Independent Director, Effective June 23, 2025 Ludwig Enterprises, Inc. appointed a new independent director, Garth Lees-Rolfe, on June 23, 2025. Garth Lees-Rolfe has over 19 years of experience in finance, accounting, and strategic financial planning. He is the current CFO of ABLi Therapeutics, Inc., a private clinical-stage biotech company since April 2025. Previously, he was the CFO of Inhibikase Therapeutics, Inc., a publicly traded global clinical-stage biotech company from April 2024 to April 2025, and the VP of Finance from November 2022 to April 2024. He also served as the Vice-President, Finance for F-Star, Inc., a publicly traded global clinical-stage biotech company from December 2021 to November 2022. Prior to that, he worked for 16 years in public practice, most of which was with Ernst & Young, most recently as Senior Manager from 2016 to 2021. Mr. Lees-Rolfe earned a Bachelor of Business from the Queensland University of Technology and a Graduate Certificate in Applied Finance from Kaplan Professional. He is a licensed Certified Public Accountant in the state of Massachusetts and a licensed Chartered Accountant of Australia and New Zealand. 
